Novartis AG NVSEF OTC

Novartis AG (NVSEF) has shown moderate revenue growth over the past 3 years, expanding from $51.8B to $57.1B (average +3.8%/yr). Net income reached $14.6B, reflecting exceptional earnings expansion at +38.9%/yr on average. The net profit margin is 25.6%, which is exceptional. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 75% (high), with a +4.9pp trend over the period. With a $299B market cap and MOAT composite score of 94/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (73/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 28-year history, the company was profitable in 28 of 28 years — a perfect long-term track record
• INCOME (85/100, Pass) — proves strong profitability and pricing power
• MOAT (94/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 73/100 with 5/7 criteria passed.